R&D Platform

The platform integrates advanced gene editing, AI-driven strain screening, vesicle-mediated nucleopeptide secretion, and continuous fermentation to enable efficient, large-scale production of structurally complex mini-proteins. This technology achieves kilogram-scale output of high-quality mini-proteins with exceptional stability and multifunctional properties, supporting the Group’s R&D efforts across pharmaceuticals, medical devices, and medical aesthetics.

Leveraging this platform, multiple repetitive and complex polypeptides have been successfully produced, addressing a strategic gap in the product portfolio between small molecule peptides and antibody-like molecules. This capability significantly enhances portfolio synergy and establishes a solid foundation for future innovation.

By utilizing polymeric materials and advanced responsive hydrogel matrices, key properties including biocompatibility, mechanical characteristics, and dynamic functionalities—such as self-healing, controlled drug release, and mesenchymal stem cell integration—are precisely regulated. This approach provides innovative regenerative solutions for repairing bone, cartilage, skin, and other tissue defects.

By seamlessly integrating drug delivery systems with tissue engineering and regenerative medicine, the platform delivers minimally invasive, highly targeted, and efficient therapeutic solutions. Current applications focus on wound healing and bone regeneration, with future research directed toward cartilage repair and organ injury recovery.